Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GlaxoSmithKline ( (GB:GSK) ) just unveiled an announcement.
GSK said the U.S. Food and Drug Administration has accepted its New Drug Application for bepirovirsen, an investigational antisense oligonucleotide for adults with chronic hepatitis B, and granted the therapy Breakthrough Therapy Designation on top of its existing Fast Track status. The move, supported by positive phase III B-Well trial data showing higher functional cure rates versus standard of care and an acceptable safety profile, underscores bepirovirsen’s potential to significantly improve outcomes in a disease that affects over 250 million people globally and could strengthen GSK’s position in hepatitis B treatment ahead of the FDA’s late-October 2026 decision date.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company that develops and commercialises vaccines, specialty medicines and other innovative therapies aimed at preventing and treating disease worldwide. The group focuses on leveraging science and technology to address high-burden conditions, positioning itself as a major player in infectious diseases and immunology with a growing pipeline of advanced therapeutics.
Average Trading Volume: 9,488,099
Technical Sentiment Signal: Buy
Current Market Cap: £80.64B
Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.